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Monitoring responses to neoadjuvant therapy in pancreatic cancer
The growing enthusiasm worldwide for neoadjuvant chemoradiotherapy in pancreatic cancer is typically
targeted at borderline resectable disease. The hope is to extend the only chance for cure (resection) to more
patients because neo-adjuvant therapy has proven capacity in some to induce tumor regression. This is borne
out in several studies comparing resection of such advanced disease with and without neoadjuvant therapy.
Typically, significant tumor down-staging (T and N status) occurs when therapy precedes operation. That said,
one should not assume that down-staging is the rule. Sadly, these same studies indicate that this occurs
infrequently. How then can we determine if and how down-staging has occurred to the extent that warrants
surgical exploration? In a small but meaningful study, Dudeja et al. evaluated radiological responses of patients
with locally-advanced pancreatic cancer who received neoadjuvant therapy. Sixteen patients received neoadju-
vant therapy over 3 years, and tumor regression, and especially major vascular involvement, could not be reliably
shown by high resolution CT in any of them. That said, 50% of borderline-resectable tumors underwent
successful margin-negative resections. Not unexpectedly, all tumors explored for locally-advanced disease
remained unresectable. The authors correctly conclude that in the absence of disease progression or metastasis,
all patients with borderline-resectable pancreatic cancer should be routinely explored after completing neoad-
juvant therapy. Since we cannot accurately monitor their treatment response radiologically, we cannot deprive
them their remote chance for cure.
Mark Callery
Hepatitis C virus, tumour and liver transplantation
Do patients with hepatocellular carcinoma (HCC) on a background of hepatitis C virus (HCV) have worse
outcomes after liver transplantation than non-HCV patients? This relatively straightforward question continues
to vex and published studies are contradictory. Molecular features of HCC which are associated with aggressive
behaviour are up-regulated in the presence of HCV, providing a biological mechanism to support the hypoth-
esis. The theory is borne out in early single centre studies, but the largest published analysis using the United
Network for Organ Sharing database published by Thuluvath in 2008 contradicted these. HCV+ patients were
shown to have a lower survival rate than HCV- patients, regardless of their HCC status. This is to be expected.
However, HCV had no additional negative impact on survival in patients with HCC. In this edition of HPB,
Dumitra and colleagues describe a further single-centre study from Montreal. They conclude that HCC+/HCV+
patients have a significantly worse outcome than those with HCC or HCV alone. So why the contradiction? It
may be that length of follow-up is important. This study provides survival curves out to 10 years. A cluster of
deaths after 5 years in the HCV+/HCC+ group results in a significantly worse outcome in this group, although
the number-at-risk are low. However, loss to follow-up is an unusually low 1.2% and explant pathology is
available for almost all patients – detail not often available in studies using administrative databases. In a
multivariable analysis controlling for recipient age, gender, MELD score and donor risk index (DRI), the
combined effect of HCC+/HCV+ gives a hazard twice that of HCC+/HCV-. HCV graft infection after liver
transplantation is universal and the course of recurrent cirrhosis accelerated. Controlling HCV recurrence with
newer antiviral agents will improve long-term survival and this study suggests the possibility of additional
benefits in HCC+/HCV+ patients. Other modifiable variables such as donor age and DRI are unlikely to have an
impact, given HCC patients rarely have the luxury of a wide choice of donor grafts.
Ewen Harrison
Understanding the significance of nodal disease in pancreatic cancer
In this issue of HPB, John et al. present a retrospective analysis of 70 patients with pancreatic adenocarcinoma
who underwent a pancreaticoduodenectomy. The aim of this study was to examine the prognostic significance
of both lymph node involvement and a redefined (by distance) resection margin. Lymph node involvement was
assessed by disease (positive or negative), burden (number of positive nodes) and ratio (positive nodes /number
nodes resected). Following multivariate analysis, only lymph node burden and lymph node ratio remained
independent prognostic factors for cancer specific survival. Resection margin irrespective of distance from
margin was not shown to be an independent factor. It is important to note that 79% of patients had metastatic
nodal involvement while only 26% underwent an R0 resection. Thus it is possible that some results are at risk
of a type II error. It would have been nice also to have known the detail with which each node was assessed. As
similar to margin analysis any inter study variation in nodal assessment could result in differing outcomes
between studies. In addition no data are provided regarding use of adjuvant therapy. Despite these limitations
this is a well conducted and thorough study especially with regard to follow up and disease recurrence. What is
interesting is that although lymph node burden and ratio were associated with worse overall survival, they were
not associated with shortened disease free survival.Whether this is just a statistical anomaly is hard to determine
but it would be very interesting in future studies to understand patterns of recurrence when comparing margin
status in those with no nodal disease. Future large studies should follow with the aim to analyse in detail nodal
involvement so that the remaining unresolved issues can be determined.
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